Mylan Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (53)

Latest Posts

About This Stock More About This Stock
Undervalued Growth And Dividend Growth In Health Technology
Article By: Chuck Carnevale
Wednesday, March 20, 2019 11:13 AM EDT
Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015.
In this article: ABBV, AGN, AMGN, BMY, BIIB, CELG, GILD, MYL, PFE, PRGO
Read
Einhorn's Greenlight Exits Apple, Buys Altice USA And BT Group
Article By: The Fly
Friday, October 5, 2018 7:24 PM EDT
David Einhorn's Greenlight Capital sold the last of its Apple (AAPL) long position on August 31 at a price of $228 per share, the firm announced in its quarterly letter sent to investors.
In this article: BT, MLM, TDG, AAPL, MU, MYL, TSLA, ATUS
Read
Above The 40 – Another Picture-Perfect Rebound Ends Stretched Conditions
Article By: Dr. Duru
Saturday, August 18, 2018 6:39 PM EDT
The recovery from the February swoon has been full of nearly predictable bounces: whether it was oversold trading conditions or support at the 50 and 200-day moving averages (DMAs). Such moves are the hallmarks of a bull market.
In this article: AMT, CMG, UVXY, AAPL, TSLA, SMH, SPY, YELP, VIX, DE, JCP, CAKE, MYL, TEVA, P, Z, RDFN, XLP
Read
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
Article By: Zacks Investment Research
Wednesday, February 28, 2018 7:00 PM EDT
Mylan N.V. reported mixed results for fourth-quarter 2017 as EpiPen sales declined. Adjusted earnings of $1.43 per share beat the Zacks Consensus Estimate of $1.41 but was down from $1.57 reported in the year-ago quarter.
In this article: MYL Also: GSK, RHHBY, TEVA
Read
Biotech Year One: A Year Of Trials Tribulations And Discovery
Article By: Kieran O'Dea
Monday, December 25, 2017 8:24 AM EDT
The biotech market is its own beast, derived from the aggregate opinions and knowledge of the mainstream thought. The market has a binary, linear, and simplistic approach to trial results ignoring the context in which each trial is conducted.
In this article: IBB, XBI, XPH, SPY, TEVA, AGN, JNJ, MYL, BMY, BIIB, PFE, MRK, INCY
Read

PARTNER HEADLINES

Latest Tweets for $MYL

No tweets yet!